Skip to content

Vertex cystic fibroisis med meets late-stage endpoints

March 29, 2017

Vertex Pharmaceuticals Inc. VRTX, +18.21% shares surged in the extended session Tuesday after the biotech drug maker said its cystic fibrosis treatment met endpoints in two late-stage clinical studies. Vertex shares rose 6.3% to $95.30 after hours, before being halted. As after-hours trading resumed, shares surged 21% to $108.60. The company said two studies showed its combination treatment of the drug tezacaftor and its branded drug Kalydeco significantly improved the lung function in cystic fibrosis patients. Vertex said it plans to submit marketing applications based on the results to both the U.S. Food and Drug Administration and the European Medicines Agency in the third quarter.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: